46 million CoronaVac vaccine purchased

0

Health Minister Eduardo Pazuello announced on Tuesday (20) that the government will buy 46 million doses of CoronaVac. The vaccine against covid-19 is produced by the Chinese laboratory Sinovac, which has the Butantan Institute as a partner in Brazil.

To guarantee the acquisition, which will only happen after the approval of the immunizer by the National Health Surveillance Agency (Anvisa), the federal government will issue a new provisional measure, providing budgetary credit of R $ 1.9 billion. In addition, R $ 80 million will also be invested in expanding the structure of Butantan.

According to Pazuello, CoronaVac doses will reach the entire country through the National Immunization Program (PNI), as soon as there is approval and registration. The delivery forecast is for December, with 6 million doses produced in China and the other 40 million manufactured by the institution linked to the government of the state of São Paulo.

Vaccination, which according to the Ministry of Health will not be mandatory, is expected to start in January 2021, depending on the results of the tests. The schedule foresees care starting with health professionals and people who are at risk for the disease caused by the new coronavirus.

Other agreements already announced

In addition to CoronaVac, the Ministry of Health has two more agreements signed for the purchase of vaccines against covid-19. One, with AstraZeneca / Oxford, foresees the distribution of 100 million doses, while the other, with the Covax initiative, led by the World Health Organization (WHO), includes 40 million doses.

Together, these three vaccines represent 186 million doses, according to the agency, which will be available in the first half of next year.

See Also
CoronaVac can be applied in Sao Paulo from January.

It is worth remembering that all of them are still in phase 3 of the clinical trial and depend on the positive results to be released and registered with Anvisa, before being released to the public.


LEAVE A REPLY

Please enter your comment!
Please enter your name here